MAIA stock forecast, quote, news & analysis

Key Takeaways

• MAIA Biotechnology is a clinical-stage immuno-oncology company developing ateganosine (THIO), a first-in-class telomere-targeting therapy for non-small cell lung cancer (NSCLC).
• Shares have traded in a narrow range near $1.18 over the trailing 30 days, reflecting a period of consolidation rather than a sharp directional move.
• The company holds U.S. FDA Fast Track designation for ateganosine in NSCLC and is advancing both a Phase 2 (THIO-101) and a pivotal Phase 3 (THIO-104) program.
• Phase 3 THIO-104 reached 65 enrolled patients, or 65% of its year-end target of 100, with an interim survival analysis expected in 2027.
• A $33 million capital raise completed in early 2026 is expected to fully fund the pivotal Phase 3 trial, and insider open-market purchases signaled management alignment.
• As a pre-revenue development-stage biotech, MAIA carries elevated clinical, regulatory, and financing risk typical of the sector.
• For additional context, review MAIA's Price Targets, Earnings, and Forecast pages.
• Explore Trending AI Robots to see how AI-driven trading strategies screen opportunities across the market.

Current Market Snapshot

MAIA Biotechnology (NYSE American: MAIA) has been trading in a comparatively tight band in recent weeks, with shares holding near the $1.15 to $1.20 level. The stock has shown limited net change over the trailing 30 days, in contrast to the more volatile swings that characterized earlier phases of the company's clinical rollout. With a market capitalization in the range of roughly $70 million, MAIA remains a small-cap, pre-revenue biotechnology name whose share price is driven primarily by clinical and regulatory milestones rather than fundamental earnings. Broader healthcare and biotechnology sentiment has remained mixed, but MAIA's price action has been anchored largely by company-specific developments tied to its ateganosine program.

MAIA Biotechnology (MAIA) Business Overview and Competitive Position

Founded in 2018 and headquartered in Chicago, MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on targeted immunotherapies for cancer. Its lead asset, ateganosine (also known as THIO or 6-thio-2'-deoxyguanosine), is described by the company as the only direct telomere-targeting anticancer agent in clinical development. The drug candidate uses a dual mechanism: it induces telomerase-dependent DNA damage in cancer cells while also activating innate and adaptive immune responses. MAIA is developing ateganosine as a third-line treatment for advanced non-small cell lung cancer in patients whose disease has progressed after checkpoint inhibitor therapy and chemotherapy, a setting with substantial unmet medical need and limited standard-of-care options. The company has also established combination agreements with Roche (atezolizumab), BeOne Medicines (tislelizumab), and sequencing with Regeneron's cemiplimab (Libtayo).

Recent Developments Driving MAIA

Over the trailing month, MAIA's news flow has centered on execution across its two leading clinical programs. In September, the company reported that enrollment in its pivotal Phase 3 THIO-104 trial had reached 65 patients, toward a stated goal of more than 100 patients dosed by the end of 2026, with an interim analysis anticipated in 2027. Regulators in Spain and Portugal cleared screening for the trial, broadening its European footprint. In October, MAIA announced that 150 patients had been treated with ateganosine sequenced with a checkpoint inhibitor across the Phase 2 and Phase 3 studies, and that Part C enrollment in THIO-101 was complete. The company has previously reported an interim 90.5% disease control rate in the efficacy-evaluable Phase 2 population, a figure it contrasts with reported 25%–35% disease control rates for standard third-line chemotherapy. A March 2026 financing of approximately $33 million is expected to fully fund the Phase 3 program, and disclosures indicated insider open-market purchases in late summer 2026.

Trending AI Robots

Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots drawn from a much larger pool that spans hundreds of strategies and thousands of tickers. Rather than displaying every available bot, the section highlights only the top-performing and most relevant systems, helping investors cut through the noise. The bots featured vary considerably in their approach, holding timeframes, and performance metrics, reflecting the diversity of algorithmic trading styles available on the platform. For traders interested in a systematic, data-driven complement to manual analysis, the page provides a straightforward entry point for evaluating which automated strategies are currently standing out.

2026 Outlook and What Investors Should Watch

Looking ahead, the central driver for MAIA remains the progress of ateganosine through late-stage development. Investors are likely to monitor enrollment progress toward the year-end 2026 target of 100 dosed patients in the Phase 3 THIO-104 trial, as well as any interim efficacy data from both the Phase 2 expansion and the pivotal study. Regulatory interactions with the FDA under the Fast Track designation, including potential pathways toward Accelerated Approval and Priority Review, represent a key catalyst. Additional factors to watch include the timing and quality of the interim overall survival analysis expected in 2027, the company's cash runway and any future financing needs, and updates on second-generation telomere-targeting molecules entering Phase 1 development. As with any clinical-stage biotech, outcomes from ongoing trials and regulatory decisions remain the primary sources of both opportunity and risk.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations